NASDAQ: INMBInmune Bio Inc Stock
$1.43-0.02 (-1.38%)
Updated Jun 22, 2026
INMB Price
$1.43
Fair Value Price
$0.83
Market Cap
$38.02M
52 Week Low
$1.09
52 Week High
$11.64
P/E
-0.86x
P/B
1.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$41.60M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.32
Operating Cash Flow
-$19M
Beta
1.58
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
INMB Overview
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INMB's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INMB
Ranked#271 of 467
Ranked#271 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.92 | A | |
| $51.35 | A | |
| $2.16 | A |
Be the first to know about important INMB news, forecast changes, insider trades & much more!
INMB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INMB ($1.43) is overvalued by 72.06% relative to our estimate of its Fair Value price of $0.83 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INMB ($1.43) is not significantly undervalued (72.06%) relative to our estimate of its Fair Value price of $0.83 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INMB due diligence checks available for Premium users.
Valuation
INMB fair value
Fair Value of INMB stock based on Discounted Cash Flow (DCF)
Price
$1.43
Fair Value
$0.83
Overvalued by
72.06%
INMB ($1.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INMB ($1.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INMB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.86x
Industry
15.1x
Market
7.94x
INMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.94x
Industry
5.1x
INMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INMB's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
INMB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$25.8M
Liabilities
$6.2M
Debt to equity
0.32
INMB's short-term assets ($22.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INMB's short-term assets ($22.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INMB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$0.0
Financing
$0.0
INMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INMB vs Biotech Stocks
Inmune Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.